A5085815516- Dermatology and Skin Diseases
- Allergic Rhinitis and Sensitization
- Food Allergy and Anaphylaxis Research
- Asthma and respiratory diseases
- Urticaria and Related Conditions
- Contact Dermatitis and Allergies
- Nail Diseases and Treatments
- Immune Cell Function and Interaction
- Mast cells and histamine
- Transgenic Plants and Applications
- Neuropeptides and Animal Physiology
- T-cell and B-cell Immunology
- Plant Pathogens and Fungal Diseases
- Herpesvirus Infections and Treatments
- Poxvirus research and outbreaks
- Olfactory and Sensory Function Studies
- Bacillus and Francisella bacterial research
- Animal testing and alternatives
- Eosinophilic Esophagitis
- Acne and Rosacea Treatments and Effects
- Toxin Mechanisms and Immunotoxins
- Autoimmune Bullous Skin Diseases
- Adrenal Hormones and Disorders
- Exercise and Physiological Responses
- Herbal Medicine Research Studies
Oregon Health & Science University
2014-2023
Oregon Health and Science University Hospital
2022
Oregon Clinic
2019
Research Network (United States)
2019
American Academy of Dermatology
2004-2016
University Dermatology
1984-2015
National Institute of Arthritis and Musculoskeletal and Skin Diseases
2014
National Institutes of Health
2014
The Lundquist Institute
2007
Kurashiki Medical Center
2007
Abstract is missing.
Abstract: Objective – To test the reliability of eczema area and severity index (EASI) scoring system by assessing inter‐ intra‐observer consistency. Design: Training evaluators, application, assessment over 2 consecutive days. Setting An academic center. Patients Twenty adults children with atopic dermatitis (AD); cohort 1 (10 patients ≥8 years) <8 years). Interventions None. Main outcome measure The EASI was used 15 dermatologist evaluators to assess in on Inter‐ intraobserver were...
BackgroundAtopic dermatitis (atopic eczema) is a chronic inflammatory skin disease that has reached epidemic proportions in children worldwide and increasing prevalence. Because of the significant socioeconomic effect atopic its on quality life families, there have been decades research focused prevention, with limited success. Recent advances cutaneous biology suggest barrier defects might be key initiators possibly allergic sensitization.ObjectiveOur objective was to test whether...
In the current study, we investigated whether Staphylococcus aureus grown from affected skin of atopic dermatitis (AD) patients secreted identifiable toxins that could act as allergens to induce IgE-mediated basophil histamine release. The S. AD were identified by ELISA using antibodies specific for staphylococcal enterotoxin (SE) exfoliative toxin (ET), or toxic shock syndrome (TSST-1). isolates 24 42 with SEA, SEB, and TSST accounting 92% isolates. 32 56 sera (57%) tested contained...
Interleukin-31 may play a role in the pathobiologic mechanism of atopic dermatitis and pruritus. We wanted to assess efficacy safety nemolizumab (CIM331), humanized antibody against interleukin-31 receptor A, treatment dermatitis.In this phase 2, randomized, double-blind, placebo-controlled, 12-week trial, we assigned adults with moderate-to-severe that was inadequately controlled by topical treatments receive subcutaneous (at dose 0.1 mg, 0.5 or 2.0 mg per kilogram body weight) placebo...
Eczema and atopic dermatitis (AD) are recognized as major health problems worldwide. Prevalence estimates high one-third of the population, depending on country studied, age range subjects, diagnostic criteria used. National prevalence for US population lacking.To examine public problem posed by eczema, AD, eczematous conditions in United States analyzing disease symptom prevalence, estimating number undiagnosed cases, assessing comorbidities.A self-administered questionnaire was sent to a...
Journal Article What the Eczema Area and Severity Index score tells us about severity of atopic dermatitis: an interpretability study Get access Y.A. Leshem, Leshem Department Dermatology Oregon Health & Science University 3303 SW Bond Avenue Portland OR 97239‐4501 U.S.A Search for other works by this author on: Oxford Academic Google Scholar T. Hajar, Hajar J.M. Hanifin, Hanifin E.L. Simpson Correspondence Eric L. Simpson. E‐mail: simpsone@ohsu.edu British Dermatology, Volume 172, Issue 5,...
BackgroundNemolizumab, an anti–IL-31 receptor A mAb, improved pruritus, dermatitis, and sleep in adults with moderate-to-severe atopic dermatitis that was inadequately controlled by topical treatments a phase II, 12-week, randomized, double-blind, placebo-controlled study (part A; NCT01986933).ObjectiveWe sought to assess the long-term efficacy safety of nemolizumab injected subcutaneously every 4 weeks (Q4W) or 8 (Q8W) 52-week, double-blind extension B).MethodsDuring part B, patients...